Monitoring for von Willebrand factor inhibitors in patients with von Willebrand disease Type 3.

被引：0
|
作者：
Miller, CH
DiMichele, DM
Hilgartner, MW
机构：
[1] NORTHWESTERN UNIV,SCH MED,CHICAGO,IL
[2] CHILDRENS MEM HOSP,CHICAGO,IL 60614
[3] CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [11] The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor
    Pergantou, H.
    Xafaki, P.
    Adamtziki, E.
    Koletsi, P.
    Komitopoulou, A.
    Platokouki, H.
    HAEMOPHILIA, 2012, 18 (03) : e66 - e67
  • [12] Von Willebrand factor and von Willebrand disease - Preface
    Michiels, JJ
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (02) : VII - VII
  • [13] Multiple von Willebrand factor mutations in patients with recessive type 1 von Willebrand disease
    Casonato, Alessandra
    Gallinaro, Lisa
    Pontara, Elena
    Bernardo, Letizia
    Sartorello, Francesca
    Daidone, Viviana
    Pagnan, Antonio
    THROMBOSIS RESEARCH, 2007, 120 (03) : 451 - 453
  • [14] Treatment of a patient with type 3 von Willebrand disease and alloantibody against von Willebrand factor
    Halimeh, S.
    Faeser, B.
    Budde, U.
    Laws, H.
    Rott, H.
    HAEMOPHILIA, 2010, 16 : 149 - 149
  • [15] Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease
    Sztukowska, M.
    Gallinaro, L.
    Cattini, M. G.
    Pontara, E.
    Sartorello, F.
    Daidone, V.
    Padrini, R.
    Pagnan, A.
    Casonato, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (01) : 107 - 114
  • [16] Reduced von Willebrand factor survival in type Vicenza von Willebrand disease
    Casonato, A
    Pontara, E
    Sartorello, F
    Cattini, MG
    Sartori, MT
    Padrini, R
    Girolami, A
    BLOOD, 2002, 99 (01) : 180 - 184
  • [17] Impact of obesity on factor VIII and von Willebrand factor levels in patients with Type 1 von Willebrand disease and low von Willebrand factor: An analysis of the ATHNdataset
    Schaefer, Beverly A.
    Cheng, Dunlei
    Kouides, Peter
    HAEMOPHILIA, 2022, 28 (01) : 109 - 116
  • [18] Pharmacokinetics of von Willebrand factor (human) in patients with von Willebrand disease (vWD)
    Menache, D
    Aronson, DL
    Kennedy, D
    Montgomery, RR
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2097 - P2097
  • [19] Pharmacokinetics of a Recombinant Von Willebrand Factor in Patients with Severe Von Willebrand Disease
    Ragni, Margaret V.
    Castaman, Giancarlo
    Gill, Joan Cox
    Kouides, Peter
    Chapman, Miranda
    Sytkowski, Arthur
    Obermann-Slupetzky, Ortrun
    Presch, Isabella
    Fritsch, Sandor
    Ewenstein, Bruce M.
    BLOOD, 2015, 126 (23)
  • [20] An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease
    Hancock, John M.
    Escobar, Miguel A.
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (03) : 157 - 161
12345